Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: Correlation of results to the individual risk profile and long-term follow-up

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 3, 2011, Pages 451-458

  Berger, Frank ^b   Friedrich, Ulla ^a   Knesewitsch, Peter ^a   Hahn, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Diagnostic 131I whole body scintigraphy; Differentiated thyroid cancer; Thyroablative therapy

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROTROPIN; THYROXINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ABLATION THERAPY; ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RISK; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING; CELL DIFFERENTIATION; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; THYROID GLAND; THYROID TUMOR; TIME; WHOLE BODY IMAGING;

ABLATION TECHNIQUES; ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THYROID GLAND; THYROID NEOPLASMS; TIME FACTORS; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 79953753720     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1657-0     Document Type: Article

References (21)

1. Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab 2008;22:989-1007.
2. Junginger T. Leitlinien der Deutschen Krebsgesellschaft e.V. zur Therapie maligner Schilddrüsentumoren. Forum Dtsch Krebsgesellschaft 1997;2:14-21.
3. Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 2007;46:206-12. German. (Pubitemid 47612287)
4. Black EG, Sheppard MC, Hoffenberg R. Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 1987;27:115-20. (Pubitemid 17085480)
5. Charles MA, Dodson Jr LE, Waldeck N, Hofeldt F, Ghaed N, Telepak R, et al. Serum thyroglobulin levels predict total body iodine scan findings in patients with treated well-differentiated thyroid carcinoma. Am J Med 1980;69:401-7. (Pubitemid 10059687)
6. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105. (Pubitemid 24221167)
7. Ronga G, Fiorentino A, Paserio E, Signore A, Todino V, Tummarello MA, et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med 1990;31:1766-71. (Pubitemid 20374507)
8. Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract 2008;14:764-74.
9. Tuttle RM, Leboeuf R, Shaha AR. Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol 2008;97:712-6. (Pubitemid 351812974)
10. Schlumberger M, Fragu P, Gardet P, Lumbroso J, Violot D, Parmentier C. A new immunoradiometric assay (IRMA) system for thyroglobulin measurement in the follow-up of thyroid cancer patients. Eur J Nucl Med 1991;18:153-7.
11. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306. (Pubitemid 28065257)
12. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8. (Pubitemid 32268810)
13. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803. (Pubitemid 43997716)
14. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12. (Pubitemid 38312801)
15. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63. (Pubitemid 32374886)
16. Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 2008;37:497-509, xi. (Pubitemid 351698085)
17. Roelants V, Nayer PD, Bouckaert A, Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:722-7. (Pubitemid 27356849)
18. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008;4:223-33. (Pubitemid 351430907)
19. Waxman A, Ramanna L, Chapman N, Chapman D, Brachman M, Tanasescu D, et al. The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 1981;22:861-5. (Pubitemid 11020541)
20. Phan TT, van Tol KM, Links TP, Piers DA, de Vries EG, Dullaart RP, et al. Diagnostic I-131 scintigraphy in patients with differentiated thyroid cancer: no additional value of higher scan dose. Ann Nucl Med 2004;18:641-6. (Pubitemid 40215911)
21. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-92.